Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Seven additional Phase 3 readouts are expected in 2026, with regulatory submissions to the FDA and EMA anticipated
Certificates of analysis from reputable laboratories can help verify that the peptide meets quality standards
Retatrutide is an investigational injectable medication developed by Eli Lilly and Company, currently undergoing late-stage clinical evaluation for the treatment of obesity and related metabolic conditions
doi: 10.1016/j.ajog.2019.04.023 7 Thurston RC, Karvonen-Gutierrez CA, Derby CA, El Khoudary SR, Kravitz HM, Manson JE
Las dosis varan entre 400 mg y 1000 mg por da
Research on histopathological alterations in the liver, kidney, and gastrointestinal system has verified the safety of this treatment
US$ 26.91
US$ 26.63
US$ 20.83
US$ 21.46
